XW01318Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8

New Technology›Anatomical Regions›Introduction
  • Billable / Specific Code
ICD-10-PCS XW01318
CMS Source: FY 2027 ICD-10-PCS dataset. Effective Oct 1, 2026 – Sep 30, 2027.FacebookXLinkedInPrint

XW01318 is a billable ICD-10-PCS procedure code for Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027). The root operation Introduction involves putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products. The Alphabetic Index lists this code under Daratumumab and Hyaluronidase-fihj. In AHRQ's Clinical Classifications Software (CCSR), this procedure falls under Chemotherapy.

Code Identity

ICD-10-PCS Code
XW01318
Billable Status
Yes — Valid for Submission
Code Describes
Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8
Short Description
Introduce Daratumumab/Hyaluronid in Subcu, Perc, New Tech 8
Parent Code
XW0

PCS Table Breakdown

Each ICD-10-PCS code is built from seven characters, each an axis of the procedure. Hover or tap the icons for the official CMS definitions.

PositionDesignationValueMeaning
1SectionXNew Technology
2Body SystemWAnatomical Regions
3Operation0Introduction
4BodyPart1Subcutaneous Tissue
5Approach3Percutaneous
6Device/Substance/Technology1Daratumumab and Hyaluronidase-fihj
7Qualifier8New Technology Group 8

In the ICD-10-PCS Alphabetic Index

The FY 2027 ICD-10-PCS Alphabetic Index refers to XW01318 as Daratumumab and Hyaluronidase-fihj. These index entries lead to this code:

Daratumumab and Hyaluronidase-fihj
Direct entry for this code
New Technology, Daratumumab and Hyaluronidase-fihj
Direct entry for this code
Iloprost
Leads to this code's table
Sarilumab
Leads to this code's table
Posoleucel
Leads to this code's table
Rezafungin
Leads to this code's table
Treosulfan
Leads to this code's table
Baricitinib
Leads to this code's table
Sabizabulin
Leads to this code's table
Tocilizumab
Leads to this code's table
Caplacizumab
Leads to this code's table
Darzalex Faspro(R)
Anatomy or device term that leads here
COVID-19 Vaccine
Leads to this code's table
Inebilizumab-cdon
Leads to this code's table
Sulbactam-Durlobactam
Leads to this code's table

To code daratumumab and hyaluronidase-fihj, open the FY 2027 ICD-10-PCS Alphabetic Index at Daratumumab and Hyaluronidase-fihj. The entry lists XW01318 directly as a complete, billable code.

Browse the full ICD-10-PCS Alphabetic Index →

Clinical Classification (CCSR)

AHRQ groups this procedure code into these clinical categories.

ADM012
Chemotherapy
Clinical domain: Administration of Therapeutic Substances

Code History

Replaces previously assigned code(s):
  • 3E013GC — Introduction of Oth Therap Subst into Subcu, Perc Approach

Similar Procedure Codes

Questions About XW01318

Is XW01318 a billable code?

Yes. This is a complete seven-character ICD-10-PCS code, specific enough to report Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 on inpatient claims from October 1, 2026 through September 30, 2027.

What is the ICD-10-PCS code for daratumumab and Hyaluronidase-fihj?

The ICD-10-PCS Alphabetic Index lists Daratumumab and Hyaluronidase-fihj under code XW01318, Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8, billable on inpatient claims in fiscal year 2027.

What do the characters in XW01318 mean?

The code breaks down character by character: the 1st character X is the Section (New Technology); the 2nd character W is the Body System (Anatomical Regions); the 3rd character 0 is the Operation (Introduction); the 4th character 1 is the BodyPart (Subcutaneous Tissue); the 5th character 3 is the Approach (Percutaneous); the 6th character 1 is the Device/Substance/Technology (Daratumumab and Hyaluronidase-fihj); the 7th character 8 is the Qualifier (New Technology Group 8).